Brookhaven Lab & Battelle collaborate on research that may lead to novel anti-microbial drugs

UPTON, NY The U.S. Department of Energy's Brookhaven National Laboratory and Battelle of Columbus, Ohio, have joined together in a Cooperative Research and Development Agreement (CRADA) to determine the structures of microbial proteins, research that may lead to the design of novel anti-microbial drugs. These drugs would be able to stop fungal or bacterial infections in patients whose immune systems are compromised, such as those with cancer or AIDS, or patients undergoing immunosuppressive therapies for organ transplantation or for the treatment of diseases such as multiple sclerosis and psoriasis.

As a first step in reaching this goal of developing new drugs, Brookhaven biologist Maria Bewley will use the National Synchrotron Light Source (NSLS) at Brookhaven to determine the structures of three proteins that are found in the metabolic pathways, or sequence of reactions catalyzed by enzymes, that enable lysine to be synthesized by microbes. Lysine is one of eight essential amino acids that humans must consume because they cannot synthesize it.

Fungi and bacteria have pathways that can synthesize lysine. The enzymes in these pathways are ideal targets for developing anti-microbial drugs, since they are absent in humans.

"We can kill fungi and bacteria if we can develop a drug that can block the enzymes in their pathways before they synthesize lysine," Bewley explained. "Since these drugs would attack enzymes that don't exist in humans, it is unlikely that they would have negative effects in the human body."

Designing such drugs, however, is hampered by the lack of structural information about the three enzymes in the lysine pathways. To obtain structural information on them, Bewley will clone and express each of the enzymes using a patented gene expression system, known as T-7, invented by Brookhaven biologists. Then she will purify each enzyme, crystallize it, and expose it to x-rays at the NSLS. A detector records a pattern from

Contact: Diane Greenberg
DOE/Brookhaven National Laboratory

Page: 1 2

Related biology news :

1. Brookhaven lab biophysicist F. William Studier wins R&D 100 award
2. Workshop for new synchrotron light source at Brookhaven
3. Brookhaven Lab expects $30 million to support life sciences
4. Brookhaven Lab develops ThraxVac to clean up anthrax
5. Rice, Brookhaven physicists decode initial stage of cell fusion
6. Brookhaven Lab scientist wins Environmental Mutagen Society Award
7. Brookhaven Spotlights: News from the National Synchrotron Light Source
8. Enzyme studies at Brookhaven Lab may lead to new antiviral agents
9. Brookhaven scientists determine key Lyme disease protein structure
10. New Brookhaven Lab study shows how ritalin works
11. New test for radiation damage to DNA developed at Brookhaven Lab

Post Your Comments:

(Date:8/7/2020)... ... 2020 , ... Nine middle school teachers from eight states ... unique professional development program that provides advanced STEM (science, technology, engineering and math) ... , Created in partnership between the National Stem Cell Foundation and The Gatton ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to ... a near term focus on Type 2 diabetes and associated comorbidities. , Justin ... therapeutic areas and classes. As Chief Commercial Officer, Justin will lead Better ...
(Date:7/10/2020)... ... July 08, 2020 , ... ... and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 ... study, but what is the most effective way to complete one? Will the ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... “We are ... Third Wave Bioactives. “It’s the only technology of its kind on the market and ... of onions with the protective capacity of traditional cultured ingredients, creating a natural way ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , ... sciences and food industries, is pleased to announce that Charles Galea has joined ... Development. , Charles is an accomplished and results-driven sales executive with over 10 ...
(Date:7/10/2020)... ... July 09, 2020 , ... PathSensors Inc., ... has expanded the company’s exclusive license to include clinical applications for CANARY™ ... market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast and highly ...
(Date:7/10/2020)... (PRWEB) , ... July 09, 2020 , ... ... to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., ... and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson ...
Breaking Biology Technology:
Cached News: